Technical Analysis for VRPX - Virpax Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 0.73 | -0.83% | -0.01 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Support | Bullish | 0.00% | |
Weak + Overbought | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
50 DMA Support | Bullish | -0.83% | |
MACD Bullish Centerline Cross | Bullish | -0.83% | |
Weak + Overbought | Other | -0.83% | |
Wide Bands | Range Expansion | -0.83% | |
Overbought Stochastic | Strength | -0.83% | |
Crossed Above 50 DMA | Bullish | 1.10% |
Alert | Time |
---|---|
10 DMA Support | about 22 hours ago |
50 DMA Support | about 22 hours ago |
Down 5% | about 22 hours ago |
Fell Below Previous Day's Low | about 22 hours ago |
Down 3% | 1 day ago |
Get a Trading Assistant
- Earnings date: 05/14/2024
Virpax Pharmaceuticals, Inc. Description
Virpax Pharmaceuticals, Inc. develops and manufactures non-opioid and non-addictive based drug compounds and drug delivery systems for pain management. It offers products, such as Probudur, an injectable bupivacaine hydrogel for postoperative pain management; Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; and NES100, an endogenous enkephalin intranasal spray for acute and chronic spray. The company develops drug delivery technologies, such as Topical metered-dose spray, Liposomal in Hydrogel encapsulation, and Enkephalin Intranasal spray. It also develops therapies to manage post-traumatic stress disorder (PTSD), as well as to help prevent viral spread, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is based in Malvern, Pennsylvania.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Health Sciences Drugs Euphoriants Opioids Influenza Pain Management Drug Delivery Analgesics Morphinans Post Traumatic Stress Disorder Heroin Drug Delivery Systems Morphine Bupivacaine Nasal Administration
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.0 |
52 Week Low | 0.3625 |
Average Volume | 203,275 |
200-Day Moving Average | 1.90 |
50-Day Moving Average | 0.69 |
20-Day Moving Average | 0.60 |
10-Day Moving Average | 0.68 |
Average True Range | 0.09 |
RSI (14) | 57.08 |
ADX | 21.52 |
+DI | 27.05 |
-DI | 17.64 |
Chandelier Exit (Long, 3 ATRs) | 0.52 |
Chandelier Exit (Short, 3 ATRs) | 0.62 |
Upper Bollinger Bands | 0.81 |
Lower Bollinger Band | 0.39 |
Percent B (%b) | 0.81 |
BandWidth | 68.54 |
MACD Line | 0.01 |
MACD Signal Line | -0.01 |
MACD Histogram | 0.0247 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.88 | ||||
Resistance 3 (R3) | 0.87 | 0.82 | 0.85 | ||
Resistance 2 (R2) | 0.82 | 0.78 | 0.82 | 0.84 | |
Resistance 1 (R1) | 0.77 | 0.75 | 0.74 | 0.78 | 0.84 |
Pivot Point | 0.72 | 0.72 | 0.70 | 0.72 | 0.72 |
Support 1 (S1) | 0.67 | 0.68 | 0.64 | 0.68 | 0.62 |
Support 2 (S2) | 0.62 | 0.65 | 0.62 | 0.61 | |
Support 3 (S3) | 0.57 | 0.62 | 0.60 | ||
Support 4 (S4) | 0.58 |